A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

  • End date
    Nov 26, 2021
  • participants needed
  • sponsor
    Celldex Therapeutics
Updated on 26 January 2021
metastatic melanoma
systemic therapy
lung cancer
pancreatic adenocarcinoma
programmed cell death 1 ligand 1
cancer chemotherapy
diffuse large b-cell lymphoma
b-cell lymphoma
mantle cell lymphoma
large b-cell lymphoma
pancreatic cancers
primary peritoneal carcinoma
peritoneal carcinoma
metastatic pancreatic adenocarcinoma
lung carcinoma


This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined.


This study will determine the MTD of CDX-1140 while also evaluating the safety, tolerability and efficacy of CDX-1140 alone (Part 1) or in combination with CDX-301 (Part 2), pembrolizumab (Part 3), or chemotherapy (Part 4) in patients with cancer.

Eligible patients that enroll to the dose-escalation portion of the study will be assigned to one of several dose levels of CDX-1140. The dose-escalation part of the study will test the safety profile of CDX-1140, alone or in combination with CDX-301, pembrolizumab or chemotherapy and determine which dose(s) of CDX-1140 will be studied in the expansion portions of the study.

All patients enrolled in the study will be closely monitored to determine if there is a response to the treatment as well as for any side effects that may occur.

Condition Non-Small Cell Lung Cancer, Adenocarcinoma, Follicular Lymphoma, Ovarian disorder, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Cholangiocarcinoma, Malignant neoplasm of kidney, Rectal disorder, Lymphoma, Breast Cancer, MALT Lymphoma, Fallopian Tube Cancer, LIVER DISEASE, Ovarian Cancer, Waldenstrom's Macroglobulinemia, Mantle cell lymphoma, Esophageal Diseases, Esophageal Cancer, melanoma, Renal Cell Carcinoma, skin cancer, HEPATIC NEOPLASM, Lymphoma, Neoplasm of unspecified nature of digestive system, Gastropathy, Gastric Cancer, head and neck cancer, Stomach Discomfort, Metastatic Melanoma, Non-Hodgkin's Lymphoma, Colon Cancer Screening, Rectal Disorders, Colon cancer; rectal cancer, Ovarian Function, Solid Tumor, Primary Peritoneal Cancer, Pancreatic Adenocarcinoma, Esophageal Carcinoma, Breast Cancer Diagnosis, Small Lymphocytic Leukemia, Transitional Cell Carcinoma of the Bladder, Other Solid Tumors, Gastric Carcinoma, Recurrent Ovarian Cancer, Bladder Urothelial Carcinoma, Indolent B-cell Lymphomas, Kidney Cancer, Esophageal Disorders, Malignant Melanoma, Liver Cancer, Malignant Adenoma, Stomach Cancer, Liver Disorders, Biliary Tract Cancer, Renal Cell Cancer, Renal Cancer, Digestive System Neoplasms, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Waldenstrom's Disease, Indolent B-cell Lymphomas, Indolent B-cell Lymphomas, Indolent B-cell Lymphomas, Indolent B-cell Lymphomas, Indolent B-cell Lymphomas, Indolent B-cell Lymphomas, Indolent B-cell Lymphomas, Indolent B-cell Lymphomas, Indolent B-cell Lymphomas, Indolent B-cell Lymphomas, Indolent B-cell Lymphomas, Indolent B-cell Lymphomas, Indolent B-cell Lymphomas, breast carcinoma, clear cell renal cell carcinoma, colorectal neoplasm, transitional cell carcinoma of bladder, non-hodgkin's lymphoma (nhl), ovarian carcinomas, cancer, ovarian, cancer ovarian, cancer of the ovary, gastric cancers, cancer, breast, esophagus cancer, oesophageal cancer, colorectal cancers, cancer, liver, cancer, hepatic, cancer, hepatocellular, liver cancers, diffuse large cell lymphoma, diffuse large b cell lymphoma, nsclc, cancer of the head and neck, fallopian tube cancers, ovarian tumors, cancer, colorectal, colorectal tumor, tumors, colorectal, cancer of the esophagus, oesophageal carcinoma, Indolent B-cell Lymphomas
Treatment Pembrolizumab, Chemotherapy, CDX-1140, CDX-301
Clinical Study IdentifierNCT03329950
SponsorCelldex Therapeutics
Last Modified on26 January 2021


Yes No Not Sure

Inclusion Criteria

Recurrent, locally advanced or metastatic melanoma (including mucosal and/or ocular), bladder/urothelial, non-small cell lung cancer, pancreatic adenocarcinoma, breast, colorectal, gastric, esophageal, renal cell, hepatic, ovarian fallopian or primary peritoneal carcinoma, head and neck, and cholangiocarcinoma. Additional tumor types (except primary CNS tumors) may be enrolled after discussion with, and approval from, the medical monitor
Must have received all standard of care therapies (approved or unapproved) as deemed appropriate by the treating physician. Patients who refuse standard therapy are excluded from the study
If of childbearing potential (male or female), agrees to practice an effective form of contraception during study treatment and for at least 3 months following last treatment
Willingness to undergo a pre-treatment and on-treatment biopsy, if required
Additional Inclusion Criteria for Part 1
Advanced diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, or indolent B-cell lymphoma are also eligible
Lymphoma patients must have received 1 prior systemic therapy
Additional Inclusion Criteria for Part 3
Patients must have documented progression while receiving anti-PD-1 or anti-PD-L1 based regimens for FDA approved indications
Patients cannot have received more than one anti-PD-1 or anti-PD-L1 based regimen
Additional Inclusion Criteria for Part 4
Patients must have metastatic pancreatic adenocarcinoma, and have not received previous treatment in a metastatic setting

Exclusion Criteria

History of severe hypersensitivity reactions to other monoclonal antibodies
Previous treatment with any anti-CD40 antibody or with FLT3L
Inadequate washout period from prior therapy as defined in the Protocol
Major surgery within 4 weeks prior to study treatment
Use of immunosuppressive medications within 4 weeks or systemic corticosteroids within 2 weeks prior to study treatment
Other prior malignancy, except for adequately treated basal or squamous cell skin cancer or in situ cancers. For all other cancers, the patient must be disease-free for at least 3 years to be allowed to enroll
Active, untreated central nervous system metastases
Active autoimmune disease or documented history of autoimmune disease
History of (non-infectious) pneumonitis or has current pneumonitis
Active infection requiring systemic therapy, known infection of HIV, Hepatitis B, or Hepatitis C
Additional Exclusion Criteria for lymphoma patients in Part 1
Prior allogenic stem cell transplantation
Patients who have received autologous stem cell transplant 12 weeks prior to the first dose of study drug
There are additional criteria your study doctor will review with you to
confirm your eligibility for the study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note